LIST OF FIGURES

Figure 4.1: DPPH radical scavenging assay dose-response curve of ascorbic acid, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean ± SE and n=3.

Figure 4.2: Metal chelating assay dose-response curve of EDTA, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean ± SE and n= 3.

Figure 4.3: Reducing power assay dose-response curve of BHA, Arab, UKMR-1 and UKMR-2 samples. Values are expressed as mean ± SE and n= 3.

Figure 4.4: Body weight of the animals treated with 1000 mg/kg body weight/ day of Arab, UKMR-1 and and UKMR-2 extracts.

Figure 4.5: Body weight of the animals treated with 1000 mg/kg body weight/ day of Arab, UKMR-1 and and UKMR-2 extracts

Figure 4.6: Cross section (200x) of kidney in mice in Normal Control group

Figure 4.7: Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of Arab extract

Figure 4.8: Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of UKMR-1 extract.

Figure 4.9: Cross section (200x) of kidney in mice treated with 1000 mg/ kg body weight/day of Arab extract.

Figure 4.10: Cross section (200x) of liver in mice Normal Control group

Figure 4.11: Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of Arab extract

Figure 4.12: Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of UKMR-1 extract

Figure 4.13: Cross section (200x) of liver in mice treated with 1000 mg/ kg body weight/ day of UKMR-2 extract

Figure 4.14: Cross section (200x) of kidney in mice in Normal Control group

Figure 4.15: Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of Arab extract.
**Figure 4.16:** Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of UKMR-1 extract.

**Figure 4.17:** Cross section (200x) of kidney in mice treated with 500 mg/ kg body weight/day of UKMR-2 extract.

**Figure 4.18:** Cross section (200x) of liver in mice Normal Control group

**Figure 4.19:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of Arab extract.

**Figure 4.20:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of UKMR-1 extract.

**Figure 4.21:** Cross section (200x) of liver in mice treated with 500 mg/ kg body weight/day of UKMR-2 extract.

**Figure 4.22:** Body weight of experimental animals in Normal control, Cholesterol control, Arab, UKMR-1 and UKMR-2 groups on day 0, 30th and 60th of experiment.

**Figure 4.23:** Triglyceride level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean ± SE and n = 6.

**Figure 4.24:** Total cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean ± SE and n = 6.

**Figure 4.25:** HDL cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean ± SE and n=6.

**Figure 4.26:** LDL cholesterol level in blood serum of experimental animals in various groups during 60 days of treatment. Values are expressed as mean ± SE and n= 6.

**Figure 4.27:** Intimal surface of the aortas from normal control group.

**Figure 4.28:** Intimal surface of the aortas from cholesterol control group of rabbits showing sudan IV stainable lipid deposit. Lipid deposits are stained brick red.
Figure 4.29: Intimal surface of the aortas from Arab extract treated group of rabbits showing sudan IV stainable lipid deposit. Lipid deposits are stained brick red.

Figure 4.30: Intimal surface of the aortas from UKMR-1 group of rabbits showing sudan IV stainable lipid deposit.

Figure 4.31: Intimal surface of the aortas from UKMR-2 group of rabbits showing sudan IV stainable lipid deposit.

Figure 4.32: Full chromatograms of Arab variety in the positive mode.

Figure 4.33: Chemical structure of gossypetin-3-O-glu-7-O-xylo/ara.

Figure 4.34: Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of Arab variety in the negative mode. (B) Fragmentation of peak at retention time 5.642 min results in a MS spectrum with m/z 300.0 dominating.

Figure 4.35: Molecular structure of herbacetin-8-O-xylo-3-O-glu.

Figure 4.36: Full chromatograms of UKMR-1 variety in the positive mode.

Figure 4.37: Fragmentation of delphinidin-3-sambubioside: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 1.779 min results in a MS spectrum with m/z 303.0 dominating.

Figure 4.38: Molecular structure of delphinidin-3-sambubioside.

Figure 4.39: Fragmentation of hibiscetin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 1.46 min results in a MS spectrum with m/z 377.0 dominating.

Figure 4.40: Chemical structure for hibiscetine.

Figure 4.41: Fragmentation of delphinidin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 6.15 min results in a MS spectrum with m/z 303.1 dominating.

Figure 4.42: Molecular structure of delphinidin.

Figure 4.43: Fragmentation of gossypetin: (A) Full chromatograms of UKMR-1 variety in the positive mode. (B) Fragmentation of peak at retention time 10.70 min results in a MS spectrum with m/z 319.2 dominating.

Figure 4.44: Molecular structure of gossypetin.
Figure 4.45: Full chromatograms of UKMR-1 variety in the negative mode.

Figure 4.46: Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of UKMR-1 variety in the negative mode. (B) Fragmentation of peak at retention time 5.315 min results in a MS spectrum with m/z 595.1 dominated.

Figure 4.47: Molecular structure of herbacetin-8-O-xylo-3-O-glu.

Figure 4.48: Fragmentation of Quercetin rutinoside: (A) Full chromatograms of UKMR-1 variety in the negative mode. (B) Fragmentation of peak at retention time 5.798 min results in a MS spectrum with m/z 609.1 dominating.

Figure 4.49: Molecular structure of quercetin rutinoside

Figure 4.50: Full chromatograms of UKMR-2 variety in the positive mode.

Figure 4.51: Fragmentation of hibiscetin: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 1.785 min results in a MS spectrum with m/z 377.0 dominating.

Figure 4.52: Chemical structure of hibiscetin

Figure 4.53: Fragmentation of delphinidin: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 5.505 min results in a MS spectrum with m/z 303.1 dominating.

Figure 4.54: Molecular structure of delphinidin.

Figure 4.55: Fragmentation of herbacetin-8-O-xylo-3-O-glu: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 1.616 min results in a MS spectrum with m/z 303.1 dominating.

Figure 4.56: Molecular structure of herbacetin-8-O-xylo-3-O-glu

Figure 4.57: Fragmentation of quercetin-3-glucoside: (A) Full chromatograms of UKMR-2 variety in the positive mode. (B) Fragmentation of peak at retention time 11.923 min results in a MS spectrum with m/z 463.3 dominating.

Figure 4.58: Chemical structure of quercetin-3-glucoside